Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

(2022) Zacchaeus Anywaine et al.   PLOS MEDICINE

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

(2021) Muhammed O Afolabi et al.   LANCET INFECTIOUS DISEASES

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

(2021) David Ishola et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

(2021) Houreratou Barry et al.   PLOS MEDICINE

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

(2021) Viki Bockstal et al.   npj Vaccines

Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis

(2020) Ravi Potluri et al.   PLoS One

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

(2020) Ramon Roozendaal et al.   npj Vaccines

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

(2020) Andrew J Pollard et al.   LANCET INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania

(2019) Zacchaeus Anywaine et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya

(2019) Gaudensia Mutua et al.   JOURNAL OF INFECTIOUS DISEASES

Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay

(2018) James Logue et al.   JOURNAL OF VIROLOGICAL METHODS

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

(2017) Ana Maria Henao-Restrepo et al.   LANCET

Epidemiologic characteristics, clinical manifestations, and risk factors of 139 patients with Ebola virus disease in western Sierra Leone

(2016) Zhe Xu et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Rural Health Care Access and Policy in Developing Countries

(2016) Roger Strasser et al.   Annual Review of Public Health

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

(2016) Iain D. Milligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The 2014 Ebola virus disease outbreak in Pujehun, Sierra Leone: epidemiology and impact of interventions

(2015) Marco Ajelli et al.   BMC Medicine

Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak

(2015) T. Yan et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014

(2015) Gabriel Fitzpatrick et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study

(2015) Luke Hunt et al.   LANCET INFECTIOUS DISEASES

Searching for the human genetic factors standing in the way of universally effective vaccines

(2015) A. J. Mentzer et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making

(2015) Maria D. Van Kerkhove et al.   Scientific Data

Influence of the microbiota on vaccine effectiveness

(2014) Yanet Valdez et al.   TRENDS IN IMMUNOLOGY

Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop

(2014) Rona Hirschberg et al.   Viruses-Basel

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates

(2012) G. Wong et al.   Science Translational Medicine

Anthrax Vaccine-Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol Challenge

(2012) M. P. Fay et al.   Science Translational Medicine

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

(2009) Nancy J. Sullivan et al.   NATURE REVIEWS MICROBIOLOGY